Articles
Welcome to The MSI Consultancy News board. This section will be regularly updated to with news and information as well as as details of some of the on going and completed projects that we feel might be of particular interest to you.
Click the titles to read each of the news items.
 |
Sandwiched between the national policy makers and the local delivery Trusts are ten regional Strategic Health Authorities. The decisions they make have a big bearing on the pharmaceutical industry – so how should we be influencing those decisions?Contributor: Gerard Doherty (01-11-2009) |
|
|
Having a compelling Payer Value Proposition is no longer optional, argues Alex Blyth.Contributor: Alex Blyth (01-11-2009) |
|
|
How career development is vital to hold on to your best peopleContributor: Paul Stuart Kregor (01-11-2009) |
|
|
Imagine that you were to acquire the Coca-Cola brand – the logo, the trademarks and the bottle shape...Contributor: Chris Marks (01-09-2009) |
|
|
Squeezing More Sales Out Of A Limited Marketing BudgetContributor: Alex Blyth (01-08-2009) |
|
|
In the current climate, job seeking pharma marketers need to be more flexible in their thinking, argues Paul Stuart-Kregor.Contributor: Dr Paul Stuart Kregor (30-07-2009) |
|
|
There’s no job for life any more, so if employers show no loyalty to staff, why should employees be loyal in return?Contributor: Dr Paul Stuart Kregor (30-07-2009) |
|
|
Pharmaceutical Focus Europe Feature Spring 2009Contributor: Gavin Gandy (30-07-2009) |
|
|
Jon Bircher turns cartographer as he suggests ways that Pharma marketers might map out the future, helping them find their way to more robust and innovative strategies.Contributor: Jon Bircher (24-07-2009) |
|
|
Analysts have said for years that the pharmaceutical industry has far too many separate companies when compared to other industry sectors, based on the relative market shares.Contributor: Dr Paul Stuart Kregor (30-05-2009) |
|
|
Pan-European marketing, particularly within the pharmaceutical industry, is a complex discipline, strongly influenced by many factors including the expansion of the EU eastwards and the emergence of new markets further afield.Contributor: Chris Marks (30-05-2009) |
|
|
Given the way the title is worded, I can almost hear a collective ‘No’ being shouted, so let’s be clear about what is actually meant here...Contributor: Gavin Gandy (30-05-2009) |
|
|
To have a car on the road once it’s more than 3 years old requires an MOT – an annual test of the cars function and suitability ensuring it meets the safety and environmental standards required.Contributor: Chris Marks (17-03-2009) |
|
|
During a debate at the NHS Confederation on the effects of recession on the NHS, former health secretaries Patricia Hewitt and Stephen Dorrell painted very different scenarios ...Contributor: Paul Stuart-Kregor (27-01-2009) |
|
|
Portfolio planning should be a practical process that delivers a programme of work to take you to sunnier shores...Contributor: Alex Blyth (27-01-2009) |
|
|
At last the ban on topping up NHS care is to be likely to be lifted in England...Contributor: Paul Stuart-Kregor (23-01-2009) |
|
|
Paul Stuart-Kregor says that the key to building a successful career is to have a plan.Contributor: Paul Stuart-Kregor (23-01-2009) |
|
|
Top-up payments – co-payment by another name?Contributor: Paul Stuart-Kregor (23-01-2009) |
|
|
Pharma marketing training is too often driven by a woolly agenda rather than by genuine business need, argues Gerard Doherty.Contributor: Gerard Doherty (23-01-2009) |
|
|
Patient involvement in decision-making is widely regarded as an important feature of good-quality healthcare.Contributor: Paul Stuart-Kregor (23-01-2009) |
|
|
Gerard Doherty from The MSI Consultancy continues his whistle-stop tour of Europe and visits Spain to look at some of the issues facing our pharmaceutical industry cousins in Southern Europe.Contributor: Gerard Doherty (27-11-2008) |
|
|
In the second of our whistle-stop tours around Europe in our ‘Postcard from…’ series we visit Slovakia.Contributor: Gerard Doherty (04-11-2008) |
|
|
From the middle of the last century, the likes of GSK, Pfizer, AstraZeneca, BMS and others have made billions...Contributor: Michael Craig (04-11-2008) |
|
|
Market access can clearly determine the potential success or failure of your brand.Contributor: Richard Jones (04-11-2008) |
|
|
In the days when the pace of change was much slower in the pharma industry, many a good career was built on finding a niche and becoming a specialist in it.Contributor: Paul Stuart-Kregor (04-11-2008) |
|
|
Whilst no-one has a crystal ball, why is the pharma industry so bad at creating future-proof strategies?Contributor: Jon Bicher (04-11-2008) |
|
|
Much ink has been spilt about the importance of measuring return on investment on marketing activity in the pharma industry...Contributor: Alex Blyth (04-11-2008) |
|
|
In an increasingly lean pharmaceutical industry maximising return on investment (ROI) is absolutely critical. However, being confident of the specific impact of your sales and marketing activities can be challenging...Contributor: Paul Stuart-Kregor (21-08-2008) |
|
|
More than any other industry, pharmaceuticals cannot exist in a one-market ‘bubble’ - and this means that dealing with different cultures is inevitable...Contributor: Paul Stuart-Kregor (10-07-2008) |
|
|
New ABPI code demands greater transparencyContributor: Paul Stuart-Kregor (10-07-2008) |
|
|
The pharma industry has traditionally lagged behind other sectors when it comes to measuring the effectiveness of its marketing activity...Contributor: Jon Bircher (10-07-2008) |
|
|
Dr Paul Stuart-Kregor argues that although global branding is a fact of life in the pharma industry...Contributor: Paul Stuart-Kregor (10-07-2008) |
|
|
As a marketer in the international pharmaceutical world, it is very likely that the brand we are responsible for has a global presence...Contributor: Michael Craig (10-07-2008) |
|
|
In this new series we take a snapshot look at some of the issues facing our Pharma colleagues within Europe...Contributor: Gerard Doherty (10-07-2008) |
|
|
Is This the Beginning of the End?Contributor: Paul Stuart-Kregor (09-07-2008) |
|
|
In the days when the pace of change was much slower in the pharma industry, many a good career was built on finding a niche and becoming a specialist in it.Contributor: Paul Stuart-Kregor (27-06-2008) |
|
|
Would you envy someone who is dying from cancer? On the face of it, probably not. After all it is the ‘Big C’.Contributor: Paul Stuart-Kregor (09-05-2008) |
|
|
Dr Richard Jones and Alex Blyth explain the meaning behind one of pharma marketing’s buzz phrases.Contributor: Richard Jones & Alex Blyth (09-05-2008) |
|
|
Here we go again! Pharmaceutical brand marketers can be forgiven for feeling that yet again they are under attack, and the bad boys and girls of the marketing world.Contributor: Paul Stuart-Kregor (05-03-2008) |
|
|
From the amount of lip service the Pharma industry pays to marketing effectiveness you might be excused for thinking it is already firmly entrenched in the industry...Contributor: Alex Blyth (29-02-2008) |
|
|
Blogs have more to offer than just a home for pharma gossip says Dominic TyerContributor: Dominic Tyer & Paul Stuart Kregor (30-01-2008) |
|
|
In this feature, we tackle the subject of the regional marketing team and look at a number of issues including, how can these regional marketing teams really add value...Contributor: Richard Jones (30-01-2008) |
|
|
A great way of achieving growth in this era of squeezed pipelines and decreasing product differentials is to maximise the market for existing products.Contributor: Paul Stuart Kregor (30-01-2008) |
|
|
Three years after the huge expansion of the EU, and with other countries such as Turkey champing at the bit to join the club, what is required to market successfully across the continent? Paul Stuart-Kregor asks whether a ‘European’ approach is really feContributor: Paul Stuart-Kregor (05-01-2008) |
|
|
Considering the development needs of pharma marketers will help both the individuals and their employers, argues Gerard Doherty of the MSI ConsultancyContributor: Gerard Doherty (05-01-2008) |
|
|
Concentrating solely on the prescriber and neglecting the patient can lead to a ‘leaky bucket’ post-launch, explains Dr Richard Jones.Contributor: Richard Jones (05-01-2008) |
|
|
Dr Paul Stuart-Kregor argues that a period spent on the consultants’ side of the fence is a big plus point in a pharma marketing career.Contributor: Paul Stuart Kregor (18-09-2007) |
|
|
In the first of a three-part series, Alex Blyth from The MSI Consultancy introduces a novel solution to the age-old problem of finding ways to deliver growth across a portfolio of in market brands.Contributor: Alex Blyth (18-09-2007) |
|
|
Communicating with key people in a rapidly changing NHS requires looking at the bigger picture - and a better understanding of what is driving those changes, says Jon Bircher.Contributor: Jon Bircher (18-09-2007) |
|
|
We all share a common commercial objective within pharmaceutical marketing - maximising peak sales for our brands.Contributor: Paul Stuart Kregor (09-07-2007) |
|
|
Whatever product or brand is chosen for the purposes of this article, somewhere high on the list of its key features will be “Improves quality of life” or a similar phrase.Contributor: Chris Marks (09-07-2007) |
|
|
The annual planning process, for all its focus on analysis, or template completion, can easily fall into the apparently comfortable tactic of merely updating the activity from last year’s plans.Contributor: Paul Stuart Kregor (09-07-2007) |
|
|
Getting prescribers to use your product requires real insight. But that is a word which is much misused and often misunderstood, says Jon Bircher.Contributor: Jon Bircher (05-07-2007) |
|
|
Too much strategic planning in the pharma industry is based on \'more of the same\'. But in a changing marketplace, what might at first seems like the safe option is anything but, says Dr Paul Stuart-Kregor.Contributor: Paul Stuart Kregor (29-05-2007) |
|
|
One of the great truisms in life is that it is better to prevent than it is to treat. This is true for both our own approach to our health and also true for our customers in the way that they view many conditions.Contributor: Chris Marks (24-05-2007) |
|
|
In recent years, the pharmaceutical industry has experienced a difficult period whereby productivity has not kept pace with increases in R&D investment. To counter this issue, an increasing number of companies have been focusing on drug repurposing.Contributor: Paul Stuart Kregor (24-05-2007) |
|
|
When it comes to New Product Development, the difference between success and failure is well-resourced high performance teams, working with validated Target Product Profiles (TPP’s) argues John Lyttle.Contributor: John Lyttle (20-02-2007) |
|
|
Launching a new product into a therapeutic area dominated by a...Contributor: Andy Newman (23-10-2006) |
|
|
Lack of innovative thinking is holding the industry back, says leading fmcg marketeerContributor: Andy Watts (23-10-2006) |
|
|
Most pharmaceutical companies are multinational, operating across many different markets.Contributor: Paul Stuart-Kregor (23-10-2006) |
|
|
As an industry, we spend millions and millions of pounds chasing new patients...Contributor: Paul Stuart-Kregor (23-10-2006) |
|
|
Earlier this year the PM Society launched its training initiative, PriMe...Contributor: Helen Lawn (23-10-2006) |
|
|
Whether you are an advocate of Sun-Tzu* or other historical texts...Contributor: Julian Trimming (17-10-2006) |
|
|
Consultancy is widely used in the pharma industry. But are consultants adding real value...Contributor: Stephen Highley (26-09-2006) |
|
|
The traditional route to a career in pharmaceutical marketing was to ‘earn your spurs’ in the sales force...Contributor: Julian Trimming (25-09-2006) |
|
|
New NHS initiatives, restructuring and Government Health Policies seem to be announced...Contributor: Jon Bircher (17-07-2006) |
|
|
As business managers, we are all faced at some time with the need to develop a forecast...Contributor: Julian Trimming (17-07-2006) |
|
|
As business managers, we are all faced at some time with the need to develop a forecast...Contributor: Julian Trimming (07-07-2006) |
|
|
How do marketers in the UK implement global branding in a way which is effective locally? Adam Fleming hears two points of view about solving this evergreen pharma marketing dilemma.Contributor: Adam Flemming (05-07-2006) |
|
|
One of the core principles of successful marketing is to understand, anticipate and satisfy the needs of our chosen customers...Contributor: Julian Trimming (19-06-2006) |
|
|
What is marketing excellence in pharmaceuticals and how do you know if you are truly excellent...Contributor: Paul Stuart Kregor (09-06-2006) |
|
|
Introducing some of the scientific rigour of the laboratory into using market intelligence can maximise the effectiveness...Contributor: Alex Blyth (09-06-2006) |
|
|
In the first two articles we discussed the value and the issues in taking this approach...Contributor: Paul Stuart Kregor (01-06-2006) |
|
|
With drug prices being squeezed, Pharma needs to act smarter to maintain profits...Contributor: Paul Stuart Kregor (18-05-2006) |
|
|
Getting your brand messages – both rational and emotional – to link with your target prescriber’s own drivers...Contributor: Paul Stuart Kregor (11-05-2006) |
|
|
Historically, marketers have been perceived as money spenders not value creators...Contributor: Julian Trimming (25-04-2006) |
|
|
How do marketers in the UK implement global branding in a way which is effective locally...Contributor: Adam Fleming (10-04-2006) |
|
|
The key to surviving patent expiry is to start planning for it right from the start of the product lifecycle...Contributor: Andy Newman (05-04-2006) |
|
|
Decreasing differentiation between products, a shorter time in which to achieve return on investment...Contributor: Paul Stuart Kregor (03-04-2006) |
|
|
Viewing a product portfolio as a group of independent entities means missing opportunities to maximise potential...Contributor: Gerard Doherty (24-03-2006) |
|
|
Back in the mists of time, marketing plans and development of the product strategy were...Contributor: Julian Trimming (21-03-2006) |
|
|
With increasingly crowded and competitive markets, decreasing product differentiation and budget...Contributor: Julian Trimming (01-03-2006) |
|
|
While few would argue that well conducted market research is a primary source of competitive advantage...Contributor: Julian Trimming (28-02-2006) |
View: Case studies | Articles | All downloads
